- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
OxyContin maker seeks approval for latest settlement plan in US
Another part of the settlement allows people recovering from addiction and those who have lost loved ones to the crisis to directly address some of the Sacklers. That court session, scheduled for Thursday, is sure to be emotional, even in a virtual setting.
New Delhi: OxyContin maker Purdue Pharma will ask a federal judge Wednesday to approve a nationwide settlement that will transform the company into public trust and contribute up to $6 billion from members of the Sackler family, with most of the money going toward efforts to ease the nation's overdose and addiction crisis.Another part of the settlement allows people recovering from addiction...
New Delhi: OxyContin maker Purdue Pharma will ask a federal judge Wednesday to approve a nationwide settlement that will transform the company into public trust and contribute up to $6 billion from members of the Sackler family, with most of the money going toward efforts to ease the nation's overdose and addiction crisis.
Read Also - USFDA approves OxyContin for children aged 11 to 16
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.